• News
  • SAN DIEGO
  • Finance

Acadia Pharmaceuticals announces equity financing

Acadia Pharmaceuticals Inc. announced a private placement equity financing and will receive gross proceeds of $86.4 million from the sale of its securities.

The biopharmaceutical company (Nasdaq: ACAD) is focused on treatments for neurological and related central nervous system disorders.

Shares of Acadia’s common stock will be sold at $4.43 per share, the closing market price on Dec. 11.

The private placement is expected to close on Dec. 17 and is subject to the satisfaction of customary closing conditions.

The anticipated proceeds from the private placement will be used primarily to support completion of Acadia’s phase 3 pimavanserin program, including its planned confirmatory phase 3 pivotal trial in Parkinson’s disease psychosis.

Jefferies & Company Inc. and Cowen and Company LLC acted as joint lead placement agents, and JMP Securities LLC acted as co-placement agent in the transaction.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Acadia Pharmaceuticals Inc.

Company Website

3911 Sorrento Valley Blvd.
San Diego, CA 92121

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ACAD
33.69
  -0.66  
- 1.92%
1,139,808,000
51.99
24.04

Insider Trade Data

Date Insider Shares Type Value
08/19/2015 Iversen, Leslie L 8,500 Exchange $93,500
08/11/2015 Kaplan, Lester J 8,500 Exchange $93,500
06/01/2015 Iversen, Leslie L 14,127 Exchange $125,024
06/01/2015 Iversen, Leslie L 14,127 Exchange $125,024
02/17/2015 Hacksell, Uli 30,000 Sell $1,028,868

Acadia Pharmaceuticals Inc. Executive(s):

Uli Hacksell

  • Chief Executive Officer, President

Similar Companies

NAICS - 541711 - Research and Development in Biotechnology
Subscribe Today!